M Jeffery Mador, MD
Pulmonary Disease · Buffalo, NYNPI 1295838233
Payments from drug & device makers
What this record shows
Astrazeneca UK Limited accounts for 75.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,908 and has fallen 92.7% since, to $140 in 2025.
Across 20 payments — averaging $125.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- AstraZeneca$186
- Inspire Medical Systems, Inc.$144
- Genentech USA, Inc.$141
- Regeneron Healthcare Solutions, Inc.$95
- Boehringer Ingelheim$45
Across 36 payments — averaging $11,263 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$295K
- Genentech, Inc.$99K
- GSK$12K
What the payments were for
- Travel & lodging$1,38955%
- Food & beverage$1,12945%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 14 | $1,908 |
| AstraZeneca | 2 | $186 |
| Inspire Medical Systems, Inc. | 1 | $144 |
| Genentech USA, Inc. | 1 | $141 |
| Regeneron Healthcare Solutions, Inc. | 1 | $95 |
| Boehringer Ingelheim | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,518 in reported general payments places this provider in the 60th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 13 | $206,613 |
| BelsomraSuvorexant | 12 | $5,258 |
| Modafinil | 20 | $789 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $508 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Buffalo
- Nashat RabadiBuffalo$613K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.